Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

NCT04022980 ·Status: COMPLETED ·Phase: PHASE1

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

NCT02268045 ·Status: COMPLETED ·Phase: PHASE3

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT00070447 ·Status: COMPLETED ·Phase: PHASE2

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

NCT01206777 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

NCT05406154 ·Status: UNKNOWN

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 ·Status: RECRUITING ·Phase: NA

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

NCT07022223 ·Status: RECRUITING ·Phase: PHASE2

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

NCT00010192 ·Status: COMPLETED ·Phase: PHASE1

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

NCT00897923 ·Status: COMPLETED

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT00003150 ·Status: COMPLETED ·Phase: PHASE3

Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research

NCT06049381 ·Status: NOT_YET_RECRUITING

A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

NCT06963632 ·Status: NOT_YET_RECRUITING

Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

NCT03688451 ·Status: UNKNOWN ·Phase: PHASE2

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

NCT01232556 ·Status: TERMINATED ·Phase: PHASE3

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01412879 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

NCT00858117 ·Status: COMPLETED ·Phase: PHASE2

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140 ·Status: TERMINATED ·Phase: PHASE2

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00290667 ·Status: COMPLETED ·Phase: PHASE2

Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

NCT00143871 ·Status: COMPLETED ·Phase: PHASE2

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

NCT02659800 ·Status: TERMINATED ·Phase: PHASE1

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721 ·Status: COMPLETED ·Phase: PHASE3

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309 ·Status: RECRUITING ·Phase: PHASE2

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990 ·Status: COMPLETED ·Phase: PHASE2

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

NCT01359592 ·Status: COMPLETED ·Phase: PHASE2